Hanmi, Bioapp Accelerate Plant-Derived Coronavirus Vaccine
Part Of Broader Multi-Biotech Push
Hanmi is accelerating development of a plant-derived COVID-19 vaccine with Bioapp after successful early, the forming part of the leading South Korean pharma group’s post-pandemic business vision, which includes 'green biotech'.
You may also be interested in...
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
A round-up of developments in the COVID-19 vaccine field from Moderna, Fosun, Merck & Co and Medicago and more.
South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.